产品
编 号：F174627
分子式：C10H16ClN3O5
分子量：293.7
分子式：C10H16ClN3O5
分子量：293.7
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
500mg
320
In-stock
1g
447
In-stock
5g
询价
询价
结构图
CAS No: 14919-77-8
产品详情
生物活性：
Benserazide hydrochloride (Serazide) is commonly used in Parkinson's disease and is an inhibitor of peripheral aromatic L-amino acid decarboxylase (AADC).
体内研究：
Benserazide (5-50 mg/kg; intraperitoneal injection; male Wistar rats) treatment of 6-OHDA-lesioned ratsincreases exogenous L-DOPA-derived extracellular DA levels, the time to reach the peak DA levels are significantly prolong by Benserazide dose-dependently. The AADC activity in the denervates striatal tissues shows a significant decrease by 10 mg/kg and 50 mg/kg Benserazide. Benserazide reduces the central AADC activity in the striatum of rats with nigrostriatal denervation, which leads to changes in the metabolism of exogenous L-DOPA.Animal Model:Male Wistar rats with 6-hydroxydopamine (6-OHDA) (8 Ag/4 Al)
Dosage:5 mg/kg, 10 mg/kg or 50 mg/kg (Pharmacokinetic study)
Administration:Intraperitoneal injection
Result:Increased in exogenous L-DOPA-derived extracellular DA levels, the time to reach the peak DA levels were significantly prolonged in a dose-dependent fashion. The AADC activity in the denervated striatal tissues showed a significant decreased by 10 mg/kg and 50 mg/kg.
体外研究：
Benserazide hydrochloride (BH) and Levodopa (LD) individually and in combination (Benserazide hydrochloride?+?LD) (25 μM; 0 hour, 12 hours, 24 hours and 168 hours; SH-SY5Y) treatment inhibit protein aggregation and have the ability to minimise the amyloid-induced cytotoxicity in human neuroblastoma cell line. Benserazide hydrochloride and LD both can act as efficient inhibitors of the formation of cytotoxic HSA aggregates, and the inhibitory effects are more pronounced when both of these drugs are added simultaneously.
Benserazide hydrochloride (Serazide) is commonly used in Parkinson's disease and is an inhibitor of peripheral aromatic L-amino acid decarboxylase (AADC).
体内研究：
Benserazide (5-50 mg/kg; intraperitoneal injection; male Wistar rats) treatment of 6-OHDA-lesioned ratsincreases exogenous L-DOPA-derived extracellular DA levels, the time to reach the peak DA levels are significantly prolong by Benserazide dose-dependently. The AADC activity in the denervates striatal tissues shows a significant decrease by 10 mg/kg and 50 mg/kg Benserazide. Benserazide reduces the central AADC activity in the striatum of rats with nigrostriatal denervation, which leads to changes in the metabolism of exogenous L-DOPA.Animal Model:Male Wistar rats with 6-hydroxydopamine (6-OHDA) (8 Ag/4 Al)
Dosage:5 mg/kg, 10 mg/kg or 50 mg/kg (Pharmacokinetic study)
Administration:Intraperitoneal injection
Result:Increased in exogenous L-DOPA-derived extracellular DA levels, the time to reach the peak DA levels were significantly prolonged in a dose-dependent fashion. The AADC activity in the denervated striatal tissues showed a significant decreased by 10 mg/kg and 50 mg/kg.
体外研究：
Benserazide hydrochloride (BH) and Levodopa (LD) individually and in combination (Benserazide hydrochloride?+?LD) (25 μM; 0 hour, 12 hours, 24 hours and 168 hours; SH-SY5Y) treatment inhibit protein aggregation and have the ability to minimise the amyloid-induced cytotoxicity in human neuroblastoma cell line. Benserazide hydrochloride and LD both can act as efficient inhibitors of the formation of cytotoxic HSA aggregates, and the inhibitory effects are more pronounced when both of these drugs are added simultaneously.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备